Claudin 18.2: from a tight junction protein to a breakthrough target in solid tumor immunotherapy
- 21 October 2026
- journal article
- Published by Taylor & Francis in Biomarkers
- p. 1-14
Abstract
No abstract availableThis publication has 64 references indexed in Scilit:
- Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and ToxicityAdvanced Science, 2026
- Identification of new immune target and signaling for cancer immunotherapyCancer Genetics, 2025
- Autocrine p40 enhances the efficacy of CLDN18.2 CAR-T cells in gastrointestinal cancerGenome Instability & Disease, 2025
- Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2Cancer Letters, 2024
- Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Cancer treatments: Past, present, and futureCancer Genetics, 2024
- Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric CancerDigestive Diseases and Sciences, 2024
- DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapyCancer Immunology, Immunotherapy, 2024
- First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detectionEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaAnnals of Oncology, 2021